🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 14 of 55

  1. Capecitabine

    The University of Hong Kong

    Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  2. Capecitabine

    The First People's Hospital of Lianyungang

    Biliary Carcinoma

    phase 2 small molecule active

    1 trial

  3. Capecitabine

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  4. Capecitabine

    Vera Therapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  5. Capecitabine

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  6. Capecitabine

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Capecitabine Accord 500 mg film-coated tablets

    Ningbo Cancer Hospital

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  8. Capecitabine+Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stomach Neoplasms

    phase 2 small molecule terminated

    1 trial

  9. Capecitabine-Oxaliplatin-Irinotecan Combination

    The First People's Hospital of Lianyungang

    Unresectable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  10. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, Doce onkovis 20 mg/ ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., Pemetrexed medac 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Vinorelbin onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed medac 100 mg Pulver für ein Konzentrat zur Herst

    Ningbo Cancer Hospital

    Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)

    phase 2 small molecule active

    1 trial

  11. Carboplatin

    Teva Pharma GmbH

    Prostatic Neoplasm

    phase 2 small molecule terminated

    1 trial

  12. Carboplatin

    Children's Hospital of Fudan University

    Central Nervous System Nongerminomatous Germ Cell Tumor

    phase 2 small molecule completed

    1 trial

  13. Carboplatin

    United Therapeutics Europe Ltd

    Recurrent Fallopian Tube Carcinoma

    phase 2 small molecule active

    1 trial

  14. Carboplatin

    United Therapeutics Europe Ltd

    Hormone Refractory Prostate Cancer

    phase 2 small molecule active

    1 trial

  15. Carboplatin

    Atrium Therapeutics

    Lung Cancer Stage II

    phase 2 small molecule active

    1 trial

  16. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Avastin 25 mg/ml concentrate for solution for infusion., Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion.

    TESARO Bio Netherlands B.V.

    Ovarian Neoplasms

    phase 2 small molecule active

    1 trial

  17. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, DOMVANALIMAB, Paclitaxel 6 mg/ml concentrate for solution for infusion, Zimberelimab

    Gilead Sciences Pty Limited

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  18. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, JNJ-61186372, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion, volrustomig, Cyramza 10 mg/ml concentrate for solution for infusion

    AstraZeneca AB

    Solid Tumors, SQ, NSQ NSCLC

    phase 2 small molecule active

    1 trial

  20. Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent

    Hoffmann-La Roche

    Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  21. Carboplatin plus Paclitaxel

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  22. Casdatifan

    Arcus Biosciences

    Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  23. Casdozokitug

    Coherus Oncology

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  24. Cediranib

    United Therapeutics Europe Ltd

    Alveolar Soft-part Sarcoma

    phase 2 small molecule active

    1 trial

  25. Celecoxib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Oral Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  26. Celecoxib

    United Therapeutics Europe Ltd

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  27. Cemiplimab

    Regeneron UK Limited

    HPV-Related Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  28. Cemiplimab

    Regeneron UK Limited

    Bladder Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  29. Cemiplimab

    Regeneron UK Limited

    Colo-rectal Cancer

    phase 2 small molecule active

    1 trial

  30. Cemiplimab

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  31. Cemiplimab

    Regeneron UK Limited

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  32. Cemiplimab

    Regeneron UK Limited

    Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  33. Cemiplimab

    Regeneron UK Limited

    Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  34. Cemiplimab

    Regeneron UK Limited

    Basal Cell Carcinoma (BCC)

    phase 2 small molecule active

    1 trial

  35. Cemiplimab

    Regeneron UK Limited

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  36. Cemiplimab

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  37. Cemiplimab

    Regeneron UK Limited

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  38. Cemiplimab

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  39. Cemiplimab

    Regeneron UK Limited

    Locally Recurrent Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  40. Cemiplimab

    Regeneron UK Limited

    Colon and Rectal Cancer

    phase 2 small molecule active

    1 trial

  41. Cemiplimab

    Regeneron UK Limited

    Locally Advanced Basal Cell Carcinoma

    phase 2 mab active

    1 trial

  42. Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  43. Cemiplimab 350 MG Intravenous Solution

    Regeneron UK Limited

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  44. Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

    Regeneron UK Limited

    Merkel Cell Carcinoma, Stage I

    phase 2 small molecule active

    1 trial

  45. Cemiplimab Plus Gemcitabine

    Regeneron UK Limited

    Pancreatic Ductal Adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  46. Cemiplimab and Fianlimab - 1, Fianlimab, Cemiplimab & Fianlimab - 2, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  47. Cemiplimab and Fianlimab - 1, Placebo, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, CARBOPLATIN, CISPLATIN, Cemiplimab & Fianlimab - 2, PACLITAXEL

    Lacuna Pharma Pty Ltd

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  48. Cemiplimab-Rwlc

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.